L-743,310

L-743,310_structure.png

L-743,310 is a chemical compound that has been studied for its potential use as an antiviral drug. It is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that was developed for the treatment of HIV/AIDS.

Mechanism of Action

L-743,310 functions by inhibiting the activity of the reverse transcriptase enzyme, which is crucial for the replication of the HIV virus. By binding to a specific site on the reverse transcriptase enzyme, L-743,310 prevents the conversion of viral RNA into DNA, thereby halting the replication process of the virus.

Pharmacokinetics

The pharmacokinetic profile of L-743,310 includes its absorption, distribution, metabolism, and excretion characteristics. It is administered orally and has been shown to have a favorable absorption profile. The compound is metabolized primarily in the liver and is excreted through the renal and fecal pathways.

Clinical Trials

L-743,310 has undergone several phases of clinical trials to evaluate its efficacy and safety in humans. Early trials demonstrated its potential in reducing viral load in patients with HIV. However, further development was halted due to the emergence of drug-resistant strains of the virus and the availability of more effective NNRTIs.

Side Effects

The side effects observed in clinical trials of L-743,310 were generally mild to moderate. Common side effects included headache, nausea, and dizziness. Serious adverse effects were rare but included liver enzyme abnormalities.

Research and Development

Research on L-743,310 has contributed to the understanding of NNRTIs and their role in HIV treatment. Although L-743,310 itself is not used clinically, the insights gained from its development have informed the design of newer and more effective NNRTIs.

Also see

• Reverse transcriptase inhibitors
• HIV/AIDS treatment
• Non-nucleoside reverse transcriptase inhibitors
• Antiviral drugs

Template:HIV/AIDS treatment Drugs for HIV Infection, in the Subclass Antiretroviral Agents

• Fusion Inhibitors (HIV)
  • Enfuvirtide, Maraviroc

• Integrase Inhibitors (HIV)
  • Dolutegravir, Elvitegravir, Raltegravir

• Monoclonal Antibodies
  • Ibalizumab

• Nonnucleoside Reverse Transcriptase Inhibitors (HIV)
  • Delavirdine, Efavirenz, Etravirine, Nevirapine, Rilpivirine

• Nucleoside Analogues (HIV)
  • Abacavir, Didanosine, Emtricitabine, Lamivudine, Stavudine, Tenofovir, Zidovudine

• Protease Inhibitors (HIV)
  • Amprenavir, Atazanavir, Darunavir, Fosamprenavir, Indinavir, Lopinavir, Nelfinavir, Ritonavir, Saquinavir, Tipranavir

Drugs for Hepatitis B

• Alpha Interferon, Adefovir, Emtricitabine, Entecavir, Lamivudine, Telbivudine, Tenofovir

Drugs for Hepatitis C

• Interferon Based Therapies
  • Alpha Interferon and Peginterferon, Ribavirin

HCV NS5A Inhibitors

• Daclatasvir, Elbasvir, Ledipasvir, Ombitasvir, Pibrentasvir, Velpatasvir

HCV NS5B Inhibitors (Polymerase inhibitors)

• Dasabuvir, Sofosbuvir

HCV Protease Inhibitors

• Asunaprevir, Boceprevir, Glecaprevir, Grazoprevir, Paritaprevir, Simeprevir, Telaprevir, Voxilaprevir

Combination Therapies

• Epclusa, Harvoni, Mavyret, Technive, Viekira Pak, Vosevi, Zepatier

Drugs for Herpes Virus

• infections (HSV), CMV, others

Acyclovir, Cidofovir, Famciclovir, Foscarnet, Ganciclovir, Valacyclovir, Valganciclovir

Drugs for Influenza

• Amantadine, Oseltamivir, Peramivir, Rimantadine, Zanamivir